One-Year CGM Cleared: Advancements in Continuous Glucose Monitoring for Diabetes
Tuesday, 24 September 2024, 11:00
One-Year CGM Cleared
The FDA has recently approved the Eversense 365, marking it as the first one-year integrated continuous glucose monitoring (CGM) system for adults diagnosed with type 1 or type 2 diabetes.
Features of Eversense 365
- Continuous monitoring of glucose levels
- Long-lasting sensor for comprehensive tracking
- Integration with mobile applications for ease of use
Osteoporosis Lawsuits Revived
In related news, lawsuits concerning osteoporosis treatments have resurfaced due to recent findings linking certain chemicals to health risks. Legal actions are underway, addressing allegations of inadequate warnings related to medications.
Concerns Over Chemical Exposure
- Potential increase in osteoporosis risk
- Emerging data on health impacts
- Importance of regulatory measures to protect public health
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.